Thomas M Bridges Selected Research

Thomas M Bridges Research Topics

Disease

17	Schizophrenia (Dementia Praecox) 01/2018 - 10/2008
6	Alzheimer Disease (Alzheimer's Disease) 12/2020 - 10/2008
4	Parkinson Disease (Parkinson's Disease) 08/2021 - 08/2009
3	Retinoblastoma (Glioblastoma, Retinal) 01/2022 - 01/2018
2	Dystonia (Limb Dystonia) 08/2021 - 08/2009
2	Central Nervous System Diseases (CNS Diseases) 08/2021 - 09/2013
2	Pain (Aches) 05/2019 - 01/2019
2	Neurobehavioral Manifestations 01/2018 - 05/2010
2	Autistic Disorder (Autism) 01/2016 - 09/2012
2	Psychotic Disorders (Schizoaffective Disorder) 03/2015 - 06/2014
2	Seizures (Absence Seizure) 09/2013 - 08/2009
2	Catalepsy 02/2012 - 10/2008
1	Retinal Degeneration 11/2021
1	Movement Disorders (Movement Disorder) 08/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2020
1	Opioid-Related Disorders (Opiate Addiction) 01/2019
1	Neoplasms (Cancer) 01/2018
1	Retinal Neoplasms 01/2018
1	Dementia (Dementias) 01/2017
1	Hypertension (High Blood Pressure) 01/2013
1	Diabetes Mellitus 01/2013
1	Fragile X Syndrome (Martin Bell Syndrome) 09/2012

Drug/Important Bio-Agent (IBA)

11	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 08/2021 - 10/2008
5	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 05/2015 - 02/2012
3	Retinaldehyde (Retinal)IBA 01/2022 - 01/2018
3	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 01/2018
2	Cholinergic Agents (Cholinergics)IBA 12/2020 - 05/2010
2	VU0466551IBA 05/2019 - 01/2019
2	Analgesics (Analgesic Drugs)IBA 05/2019 - 01/2019
2	Morphine (MS Contin)FDA LinkGeneric 05/2019 - 01/2019
2	Opioid Analgesics (Opioids)IBA 01/2019 - 01/2019
2	Dizocilpine Maleate (Dizocilpine)IBA 01/2018 - 03/2016
2	N-Methylaspartate (NMDA)IBA 03/2016 - 05/2015
2	Glutamate Receptors (Glutamate Receptor)IBA 03/2016 - 05/2015
2	Metabotropic Glutamate 5 ReceptorIBA 12/2013 - 10/2013
1	Topotecan (Hycamtin)FDA LinkGeneric 01/2022
1	Histone Deacetylases (Histone Deacetylase)IBA 11/2021
1	Histone Deacetylase InhibitorsIBA 11/2021
1	belinostatIBA 11/2021
1	Muscarinic AntagonistsIBA 08/2021
1	Neurotransmitter Agents (Neurotransmitter)IBA 08/2021
1	Opioid Receptors (Opioid Receptor)IBA 01/2019
1	Caspase 3 (Caspase-3)IBA 01/2018
1	VU0467485IBA 02/2017
1	VU0476406IBA 01/2017
1	Hypnotics and Sedatives (Sedatives)IBA 03/2016
1	5- amino- 3,4- dimethyl- N- (4- ((trifluoromethyl)sulfonyl)benzyl)thieno(2,3- c)pyridazine- 6- carboxamideIBA 03/2016
1	Clozapine (Clozaril)FDA LinkGeneric 03/2016
1	Proteins (Proteins, Gene)FDA Link 01/2016
1	VU0409551IBA 06/2015
1	Amphetamine (Amfetamine)FDA LinkGeneric 03/2015
1	Cytochrome P-450 CYP3AIBA 12/2013
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 09/2013
1	ProstaglandinsIBA 01/2013
1	ML253IBA 01/2013
1	benzocycloheptapyridineIBA 01/2013
1	compound 17IBA 01/2013
1	Prostaglandins EIBA 01/2013
1	Oxidopamine (6 Hydroxydopamine)IBA 02/2012
1	N-(3-chlorophenyl)picolinamideIBA 02/2012
1	Adenosine (Adenocard)FDA LinkGeneric 02/2012
1	2- (2- furanyl)- 7- (2- (4- (4- (2- methoxyethoxy)phenyl)- 1- piperazinyl)ethyl)- 7H- pyrazolo(4,3- e)(1,2,4)triazolo(1,5- c)pyrimidine- 5- amineIBA 02/2012
1	Haloperidol (Haldol)FDA LinkGeneric 02/2012
1	Levodopa (L Dopa)FDA LinkGeneric 02/2012
1	Muscarinic AgonistsIBA 05/2010
1	xanomelineIBA 05/2010
1	Cholinergic Antagonists (Anticholinergics)IBA 05/2010
1	Pilocarpine (Ocusert)FDA LinkGeneric 08/2009
1	N- (3- oxo- 3- (4- (pyridin- 4- yl)piperazin- 1- yl)propyl)benzo(c)(1,2,5)thiadiazole- 4- sulfonamideIBA 08/2009
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 12/2008
1	Antipsychotic Agents (Antipsychotics)IBA 10/2008

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 11/2021 - 01/2018
2	Therapeutics 08/2021 - 01/2017
1	Intravitreal Injections 01/2018